Every material Form 8-K BIODESIX INC has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Biodesix said the employment of Chief Commercial Officer Kieran O'Kane ends effective November 2, 2026. He is eligible for separation benefits under his existing Executive Severance and Change in Control Agreement, based on a qualifying termination.
Kieran O'Kane, Chief Commercial Officer, departs effective November 2, 2026, the agreed Separation Date.
Separation benefits are available under his existing Executive Severance and Change in Control Agreement, as described in the 2026 proxy statement filed April 9, 2026.
The filing does not state the dollar value of the separation benefits or name a replacement.
Biodesix reported third-quarter 2026 revenue of $24.0 million, up 10% year over year, and a net loss of $8.0 million, narrowed 8% from a year earlier. The company revised its full-year 2026 revenue guidance to $101 million to $103 million, and CEO Scott Hutton said growth was below the company's expectations, citing sales team, seasonality and development services timing issues.
Total revenue $24.0 million in Q3 2026, up 10%; Diagnostic Testing revenue $23.0 million, up 16%
Test volumes rose 24% to 19,400; gross margin was 81%, flat year over year
Net loss $8.0 million vs. $8.7 million a year earlier; Adjusted EBITDA loss $3.9 million vs. $4.6 million
Full-year 2026 revenue guidance revised to $101 million to $103 million
Biodesix reported second quarter 2026 results on August 5, 2026, with total revenue of $26.9 million, up 34% from the prior year, and a net loss of $7.3 million, down 37% from $11.5 million. The company kept its full-year 2026 revenue guidance of $108-114 million, which the filing says implies about 25% growth at the midpoint, so shareholders see both faster sales and a smaller loss with the outlook unchanged.
Diagnostic Testing revenue rose 42% to $25.4 million on a 38% increase in test volumes to 20,900
Development Services revenue fell to $1.5 million from $2.1 million, which the company attributed to timing of project completion and revenue recognition
Gross margin was 82%, up 200 basis points; Adjusted EBITDA loss narrowed to $3.2 million from $7.2 million
FY 2026 revenue guidance of $108-114 million was maintained
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BIODESIX INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →